1 Min Read
April 20 (Reuters) - TARGOVAX ASA:
* INITIATES FIRST CLINICAL TRIAL WITH TG02, THE SECOND PRODUCT FROM ITS RAS-PEPTIDE IMMUNOTHERAPY PLATFORM Source text for Eikon: Further company coverage: (Gdynia Newsroom)
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2018 Reuters. All Rights Reserved.